University Hospital Reina Sofía

Research Lines

TRANSPLANT PROGRAMME

The group has worked very actively in the network collaborating with the rest of the groups in epidemiologic and immunopathogenic projects that have permitted to improve the prognosis of the transplant population. It is remarkable the coordination of the project on tuberculosis in transplant patients (Torre-Cisneros J. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA cohort. Clin Infect Dis. 2009:15; 48:1657-65). A translational aspect of this work has been the publication of the REIPI Statement on TB (Clin Infect Dis. 2009; 48:1276-84.) and a invited editorial (Doblas A, Torre-Cisneros J. The current state of tuberculosis in solid organ transplantation: three principles for optimal management. Am J Transplant. 2011; 11:1769-70). The group coordinates an academic clinical trial of prophylaxis of tuberculosis on liver transplantation. It is also relevant the participation in the International Consensus Document on CMV and the coordination of the REIPI recommendations for the management of CMV (Enferm Infecc Microbiol Clin. 2011; 29:735-58). It has been published 25 articles in International journals, 12 coordinated by the group (6 in the firs quartile and 4 in the first decile); 13 of these 25 papers are collaborative works (10 in the first quartile and 7 in the first decile) and 7 have been coordinated by the group. The accumulated impact factor has been 130. The PI has been invited to publish 2 editorials in first decile journals. The group participle in 15 competitive projects (13 nationals and 2 autonomics): 9 are coordinated by the group (4 are collaborative projects) and 6 are coordinated by other groups. The total funds obtained have been 700.000 euro. The group has participated in 6 consensus documents: 2 published in International journals (one coordinated by the group) and 4 in nationals (2 coordinated by the group). They also collaborates 3 academic clinical trials. The group has participated in 16 epidemiologic works, 14 in collaboration (8 published in first decile journals).

RESISTENCE PROGRAMME

The principal area of interest of this group is the methicillin-resistant Staphylococcus aureus. It coordinates a project to define risk factors of MRSA pneumonia that can permit to guide empiric treatment. They also work detecting proteins that could be related with prognosis (mortality) using isolates obtained from a Reipi cohort of bacteraemia (PI 080335) and a future cohort of endocarditis. It will help to offer an individualized treatment. Finally the group work in the development of a MRSA vaccine using a proteomic based method of identification of antigens previously validated. The group has collaborated in various cohorts of bacteraemia. (multiresistant Acinetobacter baumanni, Enterobacter spp, Staphylococcus aureus, Pseudomonas aeruginosa). It could also collaborate in future clinical trials that will be necessary in some work packages. They have 14 international publications (6 coordinated by the group), mostly in collaboration with other groups (Casal M. J Antimicrob Chemother. 2009 Jul; 64(1):69-72). Eleven are included in the first quartile and one in the first decile. The group collaborates in 10 competitive founded projects. In 6 projects the principal investigator in member of the group and the rest 4 are collaborative projects with others groups. Three projects are national (FIS) and the rest are regional (Junta de Andalucía). Two projects are founded by private institutions. One is a clinical trial (FIBICO) and the other is an epidemiological collaborative study (FISEVI). The obtained funds are higher than 400.000 Euros. The group has participated in 11 epidemiological studies with other Reipi groups. Seven of these studies have been published in first quartile international journals (Peña C. Antimicrob Agents Chemother. 2012 Mar; 56 (3):1265-72).

Web Site

http://www.imibic.org/areasinvestigacion/detallegrupo/id/7

Group Coordinator

Dr. Julián de la Torre